New data for October 2013 acquired from the Health Resources and Services Administration (HRSA) Data Warehouse (replacing data for May 2013). Affected indicators:
Clinical Care
Data and maps now available for all counties with greater than 100,000 total population. Affected Indicators:
Health Outcomes
New data for 2011 acquired from the 2013 Area Health Resources File (AHRF) (replacing data for 2010). Affected indicators:
Clinical Care
Analysis was implemented to generate tract-level estimates of access to SNAP-authorized retailers. Counts of SNAP Retailers are current as of July 2013. Population estimates are from the US 2010 Decennial Census. Maps are now available at the 2010 census tract level.
New facility data acquired using the Kaiser Permanente Interchange Location API.
New analysis was implemented to produce tract-level estimates of population change between 2000 and 2010. Maps are now available at the 2010 census tract and county level. Indicator data is now available broken out by gender, race, and Hispanic origin.
New 5-year estimates for 2008-2012 acquired from the American Community Survey (replacing data for 2007-2011). Affected indicators:
Social & Economic Factors
New data acquired from the CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) Atlas interface. Affected indicators:
Health Outcomes
Data breakouts by race / ethnicity now available at the state level for Chlamydia and Gonorrhea indicators. Data breakouts by race / ethnicity now available at the state and county level for HIV Prevalence.
New maps and data now available for 2 indicators from the 2012 US Census Bureau’s SAHIE program (replacing data for 2011). Annual data depicting trends over time is now available for counties, states, and the US for 2007 through 2012. Affected indicators:
Social and Economic Factors
HP2020 values were removed from the Breast Cancer Incidence indicator table. HP2020 objective reports a benchmark of 42.1 for late-stage breast cancer. The CHNA platform indicator reports incidence rates of all breast cancer, and thus should not be compared to HP2020 objectives.